Pharvaris price target raised to $42 from $38 at Oppenheimer

Oppenheimer raised the firm’s price target on Pharvaris to $42 from $38 and keeps an Outperform rating on the shares. Pharvaris presented 2 oral presentations and 10 posters at the bradykinin symposium focused on HAE, including long-term extension data from CHAPTER-1 part 2 and RAPIDe-2, the analyst tells investors in a research note. The long-term extension results increase the firm’s confidence in deucrictibant’s differentiated profile in prophylaxis, while modestly tempering expectations in the OD setting despite strong efficacy data.